Skip to content

Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up

The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03166696
Acronym
AMIAC
Enrollment
30000
Registered
2017-05-25
Start date
2000-01-03
Completion date
2018-05-31
Last updated
2017-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction, Chronic Kidney Diseases, Mortality, Myocardial Infarction

Brief summary

A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

Interventions

None listed

Sponsors

Guangdong Provincial People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction

Exclusion criteria

* lacunar infarction

Design outcomes

Primary

MeasureTime frameDescription
all-cause mortalityfollow up until the study end (May 2018,Anticipated)all-cause mortality

Secondary

MeasureTime frameDescription
kidney outcomefollow up until the study end (May 2018,Anticipated)ESRD or 50%eGFR decline

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026